Growth Metrics

BeOne Medicines (BEIGF) Non-Current Deferred Tax Liability (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Non-Current Deferred Tax Liability for 10 consecutive years, with $97.2 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deferred Tax Liability rose 110.35% to $97.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $97.2 million through Dec 2025, up 110.35% year-over-year, with the annual reading at $97.2 million for FY2025, 110.35% up from the prior year.
  • Non-Current Deferred Tax Liability for Q4 2025 was $97.2 million at BeOne Medicines, up from $47.1 million in the prior quarter.
  • The five-year high for Non-Current Deferred Tax Liability was $97.2 million in Q4 2025, with the low at $10.8 million in Q1 2021.
  • Average Non-Current Deferred Tax Liability over 5 years is $25.7 million, with a median of $16.0 million recorded in 2023.
  • The sharpest move saw Non-Current Deferred Tax Liability dropped 18.18% in 2023, then soared 195.36% in 2025.
  • Over 5 years, Non-Current Deferred Tax Liability stood at $14.2 million in 2021, then skyrocketed by 73.46% to $24.6 million in 2022, then fell by 18.18% to $20.1 million in 2023, then soared by 129.81% to $46.2 million in 2024, then surged by 110.35% to $97.2 million in 2025.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods came in at $97.2 million, $47.1 million, and $44.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.